The Evolution of Drug Resistance in Candida

The epidemiology of Candida infections has changed in recent years. Although Candida albicans is still the main cause of invasive candidiasis in most clinical settings. The use of antifungal drugs in the therapy of fungal diseases can lead to the development of antifungal resistance. A better understanding of the mechanisms and clinical impact of antifungal drug resistance is essential for the efficient treatment of patients with Candida infection and for improving treatment outcomes. We have analysed 100 cases of positive clinical samples, such as vaginal, gastrointestinal, throat, hair, nail, skin samples. These positive Candida samples were examined for their antimycotic resistance. These samples were collected and examinated in the Laboratory of Microbiology, DRSH, Durrës, Albania. We have used seven different antimycotics: Econazole, Nystatin, Miconazole, Clotrimazole, Ketoconazole, Amphotericin, Fluconazole. It has resulted that C. albicans is more sensitive to Fluconazole and more resistente to Miconazole. So, we can say that the best antimycotic for C. albicans infections is Fluconazole.